Fetal and neonatal alloimmune thrombocytopenia

Published on 14/04/2017 by admin

Filed under Pediatrics

Last modified 14/04/2017

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1353 times

Figure 16.1

Suggested management plan. CS: cesarean section; FNAIT: fetal and neonatal alloimmune thrombocytopenia; HPA: human platelet antigen; ICH: intracranial hemorrhage; IVIG: intravenous immunoglobulin; MRI: magnetic resonance imaging; US, USS: ultrasound scan; FBS: fetal blood sampling; IUPT: intrauterine platelet transfusion.

Key learning points

  • FNAIT is rare but a potentially disastrous condition.

  • Management should focus on prevention of ICH.

  • The majority of ICH occurs during intrauterine life.

  • There is a lack of good quality evidence to guide management.

  • The index pregnancy is the most important factor for risk estimation of ICH.

  • Maternal IVIG administration appears to reduce risk of ICH even when the platelet count shows no response.


1.Williamson LM, Hackett G, Rennie J, et al. The natural history of fetomaternal alloimmunization to the paltelet-specific antigen PA-1a (PIA1, Zwa) as determined by antenatal screening. Blood 1998; 92: 22807.
2.Serrarens-Janssen v M, Steegers EA, van den Bos A, et al. Experiences with fetomaternal alloimmune thrombocytopenia in the Netherlands over a 2-year period. Acta Obstetrica et Gynecologica Scandinavica 2005; 84: 203.
3.Knight M, Pierce M, Allen D, et al. The incidence and outcome of fetomaternal alloimmune thrombocytopenia: a UK national study using three data sources. Br J Haematol 2011; 152: 4608.
Buy Membership for Pediatrics Category to continue reading. Learn more here